Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study).

Trial Profile

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Nucleosides; Nucleotides
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms PEGON
  • Most Recent Events

    • 17 Mar 2017 Primary endpoint (Sustained response) has not been met.
    • 17 Mar 2017 Primary endpoint (Response at week 96) has not been met.
    • 17 Mar 2017 Results assessing safety and efficacy of peginterferon in HBeAg-positive patients (n=77) and in the subgroup of interferon-naive patients (n=58), published in the Journal of Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top